Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Masked, Placebo-Controlled, Dose- Finding, Non-Inferiority Study of X-82 Plus Prn Intravitreal (Ivt) Anti-VEGF Compared to Prn Ivt Anti-VEGF Monotherapy in Neovascular AMD
Conditions
Interventions
X-82
Anti-VEGF
+1 more
Locations
35
United States
Tucson, Arizona, United States
Beverly Hills, California, United States
Huntington Beach, California, United States
Redlands, California, United States
Sacramento, California, United States
Colorado Springs, Colorado, United States
Start Date
March 16, 2015
Primary Completion Date
December 12, 2017
Completion Date
January 12, 2018
Last Updated
February 11, 2022
NCT07440225
NCT05407636
NCT07308639
NCT07441642
NCT05913063
NCT07144137
Lead Sponsor
Tyrogenex
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions